5.1 Opioid Prescribing Limits, Acute Pain Rules & MME Thresholds

Opioid Prescribing Limits, Acute Pain Rules & MME Thresholds

Quick Answer: Under 18VAC85-21-40, as amended effective January 2, 2025, a prescriber treating acute or subacute pain shall not prescribe an opioid in a quantity exceeding a 14-day supply, unless extenuating circumstances are clearly documented. Opioids prescribed as part of a surgical procedure are likewise limited to no more than 14 consecutive days and to the immediate perioperative period. Initiation must be with short-acting opioids. For all patients, the prescriber must document reasons to exceed 50 MME/day, and before exceeding 120 MME/day must document reasonable justification or refer to/consult a pain management specialist. An FDA-approved opioid reversal agent must be prescribed when any of four risk factors is present: prior overdose, substance misuse, doses in excess of 120 MME/day, or concomitant benzodiazepine. Chronic pain adds a written agreement, urine drug screening at initiation and at least annually, and PMP queries and rationale review at least every three months.

⚠ Currency warning — the 7-day figure is obsolete. Virginia's original 2017-2018 rule capped acute-pain opioids at a 7-day supply, and that number is still printed across older review books, flashcard decks, and CE handouts. The Board of Medicine replaced it with a 14-day cap effective January 2, 2025. Likewise, the naloxone co-prescribing trigger is 120 MME/day, not 50 MME/day. Answer from the current regulation.

---

1. Statutory Authority & Joint Regulatory Framework

In response to the nationwide opioid epidemic, the Virginia General Assembly enacted statutory mandates directing the Virginia Board of Medicine and the Virginia Board of Pharmacy to promulgate joint regulations governing the prescribing and dispensing of opioid medications. These binding administrative rules are codified at 18VAC85-21-10 et seq. (Regulations Governing Prescribing of Opioids and Buprenorphine).

Under both federal law (21 CFR § 1306.04) and Virginia law (Code of Virginia § 54.1-3303), a prescription for a controlled substance is lawful only if issued for a legitimate medical purpose by an individual practitioner acting in the usual course of professional practice. The dispensing pharmacist bears an inescapable corresponding responsibility to verify that opioid prescriptions comply with statutory supply ceilings, formulation restrictions, and clinical safety thresholds before releasing medication to the patient.

                      Virginia Opioid Regulatory Hierarchy
  ┌────────────────────────────────────────────────────────────────────────┐
  │                       Code of Virginia § 54.1-3303                      │
  │               (Bona Fide Practitioner-Patient Relationship)             │
  └───────────────────────────────────┬────────────────────────────────────┘
                                      │
  ┌───────────────────────────────────▼────────────────────────────────────┐
  │                     18VAC85-21-10 et seq. (Joint Rules)                │
  │        Board of Medicine & Board of Pharmacy Prescribing Mandates       │
  └───────────────────┬────────────────────────────────┬───────────────────┘
                      │                                │
       ┌──────────────▼──────────────┐  ┌──────────────▼──────────────┐
       │ Part II: Acute Pain Rules   │  │ Part III: Chronic Pain Rules│
       │ • Max 14-day supply         │  │ • Treatment Agreement       │
       │ • Short-acting only         │  │ • Baseline & Annual UDS     │
       │ • No ER/LA formulations     │  │ • PMP Query Every 90 Days   │
       └─────────────────────────────┘  └─────────────────────────────┘

---

2. Acute Pain Prescribing Mandates (18VAC85-21-30 & 40)

Under 18VAC85-21-20, acute pain is defined as pain that occurs typically and characteristically after injury, trauma, or surgery and is expected to last less than three (3) months.

Non-Opioid First-Line Requirement

Before initiating opioid therapy for acute pain, prescribers must consider non-pharmacologic interventions (physical therapy, ice, immobilization) and non-opioid pharmacologic therapies (acetaminophen, NSAIDs, topical analgesics). Opioids should be initiated only when clinical severity dictates that alternative non-opioid analgesics are insufficient or medically contraindicated.

Duration and Quantity Limitations

Virginia enforces rigid statutory limits on outpatient acute opioid prescribing:

1. Standard Limit — 14-Day Supply (18VAC85-21-40 A 1): A prescriber providing treatment for acute or subacute pain shall not prescribe a controlled substance containing an opioid in a quantity that exceeds a 14-day supply, unless extenuating circumstances are clearly documented in the medical record.
2. Surgical Procedures (18VAC85-21-40 A 2): An opioid prescribed as part of treatment for a surgical procedure shall be for no more than 14 consecutive days and within the immediate perioperative period, again unless extenuating circumstances are clearly documented. Note that surgery is not an enlargement of the 14-day ceiling — it is a parallel rule that adds the perioperative-window restriction on top of the same 14-day cap.
3. Prohibition on Speculative Pre-Prescribing: Prescribers may not write post-operative opioid prescriptions in advance of an elective surgery or hospital discharge to be filled speculatively by the patient before the surgical event occurs.
4. Quantity Proration: The quantity prescribed must not exceed the exact number of doses needed for the expected duration of acute pain, even if the authorized days supply is under the statutory ceiling.

Formulation Restrictions: Short-Acting Only

Under 18VAC85-21-30(C), prescribers shall only prescribe short-acting opioids for acute pain.

Strict Clinical Prohibition: Long-acting, extended-release, or continuous-release opioids are strictly contraindicated and prohibited for acute pain. This statutory ban encompasses medications such as:

• Oxycodone extended-release (OxyContin)
• Morphine sulfate extended-release (MS Contin, Kadian)
• Fentanyl transdermal patches (Duragesic)
• Methadone oral solutions or tablets
• Oxymorphone extended-release

If a community pharmacist receives a new prescription for transdermal fentanyl or OxyContin written for an opioid-naive patient following a sports injury or dental extraction, dispensing this prescription violates Virginia law. The pharmacist must refuse the order or contact the prescriber immediately to cancel it.

---

3. Morphine Milligram Equivalent (MME) Thresholds & Dosage Checkpoints

The Morphine Milligram Equivalent (MME) is a standardized clinical metric that equates the potency of various opioid analgesics to oral morphine. Calculating the total daily MME allows clinicians and pharmacists to quantify overdose risk across single or multi-drug regimens.

$\text{Daily MME} = \sum \Big( \text{Strength per Unit (mg)} \times \text{Units Taken per Day} \times \text{MME Conversion Factor} \Big)$

Reference MME Conversion Factors

The 50 MME/day Assessment Threshold (18VAC85-21-40 & 70)

When a patient's total daily opioid dosage reaches or exceeds 50 MME/day, Virginia regulations mandate enhanced clinical scrutiny:

• The prescriber must perform a careful clinical assessment documenting the clinical rationale for the dose.
• The prescriber must evaluate whether the therapeutic benefits outweigh the heightened risk of respiratory depression, sedation, and opioid use disorder.
• The patient's medical record must contain a comprehensive treatment plan justifying continuation or escalation above 50 MME/day.

The 120 MME/day Specialist Consultation Threshold

When an opioid regimen approaches or exceeds 120 MME/day, the risk of fatal overdose increases exponentially. Under 18VAC85-21-40(C) and 18VAC85-21-70(C):

• The prescriber must document a consultation with a board-certified pain management specialist; or
• The prescriber must enter an extensive clinical justification in the medical record explaining why the dose is necessary and why a pain specialist consultation was either unobtainable, delayed, or medically unfeasible.

---

4. Mandatory Prescribing of an Opioid Reversal Agent

Virginia does not leave naloxone to clinical preference; it is an affirmative regulatory obligation. The identical requirement appears twice — at 18VAC85-21-40 B 3 for opioid initiation in all patients, and at 18VAC85-21-70 for chronic pain.

The Four Statutory Triggers

An FDA-approved opioid reversal agent shall be prescribed for any patient when any one of the following risk factors is present:

1. Prior overdose — a documented history of overdose.
2. Substance misuse — documented misuse of controlled substances.
3. Doses in excess of 120 MME/day — note this is 120, not 50.
4. Concomitant benzodiazepine — a benzodiazepine prescribed alongside the opioid.

The 50-versus-120 distinction is the whole question. 50 MME/day is a documentation threshold: the prescriber must "carefully consider and document in the medical record the reasons to exceed 50 MME/day" (18VAC85-21-40 B 1). 120 MME/day is where the obligations escalate — it is both the specialist-consultation-or-justification threshold (B 2) and a reversal-agent trigger (B 3). A patient at 75 MME/day with no other risk factor requires documented rationale but not a mandatory reversal agent.

The Separate Co-Prescribing Restriction (18VAC85-21-40 C)

Because of the higher risk of fatal overdose, a prescriber shall co-prescribe an opioid with a benzodiazepine, sedative hypnotic, carisoprodol, or tramadol (an atypical opioid) only when there are extenuating circumstances, and shall document a tapering plan to reach the lowest possible effective doses. Note that carisoprodol and tramadol appear by name — a frequently missed detail, since neither is a benzodiazepine.

Pharmacist Role & the Virginia Naloxone Standing Order

If an opioid prescription arrives with a reversal-agent trigger present and no accompanying naloxone order, the pharmacist should intervene. Under the Virginia statewide standing order for naloxone, a Virginia-licensed pharmacist may dispense naloxone (for example Narcan nasal spray 4 mg or Kloxxado nasal spray 8 mg) to any person at risk of experiencing or witnessing an opioid overdose without an individual prescription. See Section 4.4 for the standing-order mechanics.

---

5. Chronic Pain Prescribing Regulations (18VAC85-21-60 through 120)

Under 18VAC85-21-20, chronic pain is defined as non-malignant pain that has persisted for three (3) months or longer, or beyond the normal healing time of tissue injury. Chronic pain rules do not apply to palliative care, hospice patients, or active cancer pain management.

Core Regulatory Mandates for Chronic Opioid Therapy

Required Components of the Written Treatment Agreement

The formal treatment agreement executed between the prescriber and chronic pain patient must explicitly state:

• The patient must receive all controlled substance prescriptions exclusively from the designated primary prescriber (or designated covering partner). (These agreement terms are common Virginia practice standards implementing 18VAC85-21-90; the regulation specifies the required subject matter rather than fixed contract wording.)
• The patient must fill all controlled substance prescriptions at a single designated pharmacy.
• The patient must take medications strictly as directed, without unauthorized dose self-escalation or sharing.
• The patient agrees to submit to random pill counts and unannounced urine or serum drug testing within a specified timeframe (e.g., 24–48 hours of notification).
• The patient acknowledges that failure to adhere to the agreement, diversion, illicit substance use, or abusive behavior constitutes grounds for immediate opioid tapering and discontinuation.

Buprenorphine Prescribing Rules (18VAC85-21-130 et seq.)

When prescribing buprenorphine for opioid use disorder (OUD) or chronic pain:

• Combination Formulations Preferred: Buprenorphine co-formulated with naloxone (Suboxone, Zubsolv) is the mandatory standard for OUD to deter intravenous diversion.
• Mono-Product Restrictions: Buprenorphine mono-product (Subutex) is strictly restricted to pregnant patients, nursing mothers, or patients with a documented, severe, life-threatening adverse reaction to naloxone.
• Daily Ceiling: Daily dosages for OUD should not exceed 24 mg/day without documented clinical justification and consultation.